BlinkLab (ASX:BB1) said its European attention-deficit/hyperactivity disorder (ADHD) study, being conducted in collaboration with Mental Care Group, completed participant recruitment and the firm's neurometric data collection, enrolling 375 children, according to a Friday Australian bourse filing.
The study is designed to evaluate the firm's objective neurometric measures against comprehensive clinical ADHD diagnoses. The clinical diagnostic reference dataset, completed in the final stage of the study, will be used to evaluate the neurometric measures against diagnostic standards for ADHD.
Its shares fell 3% in recent trading on Friday.